[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"biomarker:dll3-gene":3},{"name":4,"total":5,"recruiting":6,"trials":7},"DLL3 Gene",8,7,[8,16,23,29,35,41,47,53],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT06592638","A Phase 1 Dose Escalation Study of ZG006 in Patients With Small Cell Lung Cancer",[12],"Phase 1","RECRUITING","2026-08-26T02:15:26.669629Z","2026-05-05T02:43:27.643282Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT07278479","Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors",[20],"Phase 1\u002FPhase 2","2026-08-26T02:16:16.169331Z","2026-05-05T02:43:28.190947Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":27,"content_modified":28},"NCT06814496","Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors",[20],"2026-08-26T02:15:38.131683Z","2026-07-24T01:27:14.891188Z",{"nct_id":30,"title":31,"phases":32,"status":13,"updated_at":33,"content_modified":34},"NCT05652686","A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)",[20],"2026-08-26T02:16:14.341106Z","2026-07-19T19:36:05.121911Z",{"nct_id":36,"title":37,"phases":38,"status":13,"updated_at":39,"content_modified":40},"NCT04429087","A Study to Test Different Doses of Obrixtamig in Patients With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3",[12],"2026-08-03T00:53:42.755927Z","2026-07-05T05:32:16.773103Z",{"nct_id":42,"title":43,"phases":44,"status":13,"updated_at":45,"content_modified":46},"NCT07080242","Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors",[12],"2026-08-26T02:15:59.318403Z","2026-07-05T05:32:16.735201Z",{"nct_id":48,"title":49,"phases":50,"status":13,"updated_at":51,"content_modified":52},"NCT04199741","PET\u002FCT Imaging of Small Cell Lung Cancer Using 89Zr-DFO-SC16.56",[20],"2026-08-26T02:18:04.640417Z","2026-07-05T05:32:16.773657Z",{"nct_id":54,"title":55,"phases":56,"status":57,"updated_at":58,"content_modified":59},"NCT06941480","A Study of 177Lu-DTPA-SC16.56 in People With Neuroendocrine Carcinomas of the Lung and Prostate",[12],"NOT_YET_RECRUITING","2026-08-26T02:16:58.658552Z","2026-05-05T02:43:27.575511Z"]